Illumina Inc.

233.56+16.14+7.42%Vol 1.76M1Y Perf -41.78%
May 13th, 2022 16:00 DELAYED
BID230.00 ASK231.49
Open223.10 Previous Close217.42
Pre-Market232.92 After-Market-
 -0.64 -0.27%  - -
Target Price
411.55 
Analyst Rating
Moderate Buy 2.33
Potential %
76.21 
Finscreener Ranking
★★★★     53.21
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     52.81
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     69.37
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
7.94 
Earnings Rating
Strong Buy
Market Cap36.69B 
Earnings Date
5th May 2022
Alpha0.00 Standard Deviation0.10
Beta0.99 

Today's Price Range

221.81235.63

52W Range

208.35526.00

5 Year PE Ratio Range

29.20124.90

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-6.22%
1 Month
-30.59%
3 Months
-29.11%
6 Months
-39.09%
1 Year
-41.78%
3 Years
-23.31%
5 Years
28.06%
10 Years
418.56%

TickerPriceChg.Chg.%
ILMN233.5616.14007.42
AAPL147.114.55003.19
GOOG2 330.3167.09002.96
MSFT261.125.77002.26
XOM88.862.56002.97
WFC42.640.83001.99
JNJ176.85-1.0200-0.57
FB198.627.38003.86
GE75.051.77002.42
JPM119.091.05000.89
Financial StrengthValueIndustryS&P 500US Markets
1.80
2.50
0.19
0.24
15.50
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
69.70
20.90
26.40
27.00
17.87
RevenueValueIndustryS&P 500US Markets
3.43B
21.85
8.03
11.06
Earnings HistoryEstimateReportedSurprise %
Q01 20220.871.0722.99
Q04 20210.500.7550.00
Q03 20211.241.4516.94
Q02 20211.361.8737.50
Q01 20211.361.8938.97
Q04 20201.211.220.83
Q03 20200.771.0232.47
Q02 20200.720.62-13.89
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.920.00-
9/2022 QR1.11-1.77Negative
12/2022 FY4.140.73Positive
12/2023 FY5.26-10.24Negative
Next Report Date-
Estimated EPS Next Report0.87
Estimates Count7
EPS Growth Next 5 Years %31.20
Volume Overview
Volume1.76M
Shares Outstanding157.10K
Shares Float136.43M
Trades Count45.73K
Dollar Volume408.07M
Avg. Volume1.40M
Avg. Weekly Volume2.18M
Avg. Monthly Volume1.10M
Avg. Quarterly Volume918.08K

Illumina Inc. (NASDAQ: ILMN) stock closed at 233.56 per share at the end of the most recent trading day (a 7.42% change compared to the prior day closing price) with a volume of 1.76M shares and market capitalization of 36.69B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 7850 people. Illumina Inc. CEO is Francis A. DeSouza.

The one-year performance of Illumina Inc. stock is -41.78%, while year-to-date (YTD) performance is -38.61%. ILMN stock has a five-year performance of 28.06%. Its 52-week range is between 208.35 and 526, which gives ILMN stock a 52-week price range ratio of 7.94%

Illumina Inc. currently has a PE ratio of 49.60, a price-to-book (PB) ratio of 3.64, a price-to-sale (PS) ratio of 10.10, a price to cashflow ratio of 69.00, a PEG ratio of 2.32, a ROA of 6.84%, a ROC of 8.20% and a ROE of 10.09%. The company’s profit margin is 17.87%, its EBITDA margin is 26.40%, and its revenue ttm is $3.43 Billion , which makes it $21.85 revenue per share.

Of the last four earnings reports from Illumina Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.87 for the next earnings report. Illumina Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Illumina Inc. is Moderate Buy (2.33), with a target price of $411.55, which is +76.21% compared to the current price. The earnings rating for Illumina Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Illumina Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Illumina Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.71, ATR14 : 16.53, CCI20 : -106.40, Chaikin Money Flow : -0.19, MACD : -30.38, Money Flow Index : 27.94, ROC : -21.50, RSI : 28.87, STOCH (14,3) : 23.16, STOCH RSI : 0.78, UO : 33.07, Williams %R : -76.84), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Illumina Inc. in the last 12-months were: Aimee L. Hoyt (Option Excercise at a value of $0), Aimee L. Hoyt (Sold 3 646 shares of value $1 446 750 ), Alexander Aravanis (Sold 12 404 shares of value $5 162 858 ), Caroline D. Dorsa (Sold 1 000 shares of value $450 000 ), Charles E. Dadswell (Option Excercise at a value of $0), Charles E. Dadswell (Sold 5 086 shares of value $2 170 879 ), Francis A. DeSouza (Option Excercise at a value of $0), Jay T. Flatley (Sold 4 000 shares of value $1 518 120 ), Joydeep Goswami (Option Excercise at a value of $0), Kevin Carl Pegels (Option Excercise at a value of $0), Phillip G. Febbo (Option Excercise at a value of $0), Phillip G. Febbo (Sold 3 988 shares of value $1 570 118 ), Sam A. Samad (Option Excercise at a value of $0), Susan H. Tousi (Option Excercise at a value of $0), Susan H. Tousi (Sold 6 200 shares of value $2 840 000 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (33.33 %)
3 (33.33 %)
4 (30.77 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
6 (66.67 %)
6 (66.67 %)
8 (61.54 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
1 (7.69 %)
Summary RatingModerate Buy
2.33
Moderate Buy
2.33
Moderate Buy
2.54

Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.

CEO: Francis A. DeSouza

Telephone: +1 858 202-4500

Address: 200 Illumina Way, San Diego 92122, CA, US

Number of employees: 7 850

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%37%

Bearish Bullish

60%40%

Bearish Bullish

61%39%

TipRanks News for ILMN

Tue, 10 May 2022 12:05 GMT Analysts Offer Insights on Healthcare Companies: Heska (HSKA), Illumina (ILMN) and Owens & Minor (OMI)

- TipRanks. All rights reserved.

Sat, 07 May 2022 03:37 GMT Illumina (ILMN) Gets a Hold Rating from Robert W. Baird

- TipRanks. All rights reserved.

Wed, 30 Mar 2022 09:07 GMT OTR Global Upgrades Illumina (ILMN) to Buy

- TipRanks. All rights reserved.

Thu, 03 Mar 2022 01:10 GMT Illumina (ILMN) was Upgraded to a Hold Rating at Credit Suisse

- TipRanks. All rights reserved.

Thu, 06 Jan 2022 14:05 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (BMRN), Illumina (ILMN) and Catalent (CTLT)

- TipRanks. All rights reserved.

News

Stocktwits